Laser-assisted Ultrasound-guided Peripheral Vein Cannulation in Cardiac Surgery
Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Jul 14, 2025
Trial Information
Current as of August 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help doctors place a small tube, called a catheter, into a vein during heart surgery. Usually, doctors use ultrasound (a type of imaging that uses sound waves) to guide them, but this study is testing whether adding a laser tool can make it easier and more successful on the first try. The goal is to see if this laser-assisted method helps doctors insert the catheter more quickly and accurately compared to the traditional ultrasound method.
Adults between 18 and 80 years old who are having heart surgery and meet certain health criteria, such as a healthy weight range and a specific health status, may be able to take part. People with infections or bruises where the catheter would go, those who can’t cooperate with the procedure, or those who don’t want to join won’t be able to participate. If you join the study, you’ll experience the usual catheter placement but with either the laser-assisted or traditional ultrasound guidance, and the doctors will check which method works better. This study hasn’t started recruiting participants yet, but it could help improve care for future patients undergoing heart surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. aged 18-80 years
- • 2. BMI 18-30 kg/m²
- • 3. ASA classification 1-4
- Exclusion Criteria:
- • 1. infection or hematoma at the puncture site
- • 2. patients mentally unstable or unable to cooperate
- • 3. patient refused to participate
About Nanjing First Hospital, Nanjing Medical University
Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Shuai Wang
Study Chair
Nanjing First Hospital, Nanjing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported